Edgestream Partners’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.48M | Buy |
151,779
+66,027
| +77% | +$3.59M | 0.19% | 169 |
|
|
2026
Q1 | $5.38M | Buy |
85,752
+66,293
| +341% | +$5.3M | 0.18% | 212 |
|
|
2025
Q4 | $1.86M | Sell |
19,459
-1,851
| -9% | -$181K | 0.05% | 555 |
|
|
2025
Q3 | $2.08M | Buy |
+21,310
| New | +$2.21M | 0.06% | 521 |
|
|
2025
Q2 | – | Sell |
-2,338
| Closed | -$236K | – | 860 |
|
|
2025
Q1 | $236K | Sell |
2,338
-20,766
| -90% | -$2.09M | 0.01% | 786 |
|
|
2024
Q4 | $2.06M | Buy |
+23,104
| New | +$2.03M | 0.09% | 392 |
|
|
2024
Q3 | – | Sell |
-8,796
| Closed | -$677K | – | 854 |
|
|
2024
Q2 | $677K | Buy |
8,796
+3,455
| +65% | +$253K | 0.03% | 615 |
|
|
2024
Q1 | $366K | Buy |
+5,341
| New | +$343K | 0.02% | 690 |
|
|
2023
Q3 | – | Sell |
-8,930
| Closed | -$483K | – | 824 |
|
|
2023
Q2 | $483K | Buy |
+8,930
| New | +$466K | 0.04% | 534 |
|
|
2022
Q3 | – | Sell |
-27,073
| Closed | -$1.01M | – | 460 |
|
|
2022
Q2 | $1.01M | Sell |
27,073
-21,769
| -45% | -$886K | 0.08% | 322 |
|
|
2022
Q1 | $2.16M | Sell |
48,842
-21,385
| -30% | -$927K | 0.17% | 199 |
|
|
2021
Q4 | $2.98M | Sell |
70,227
-110,764
| -61% | -$4.65M | 0.19% | 163 |
|
|
2021
Q3 | $7.85M | Sell |
180,991
-208,472
| -54% | -$9.22M | 0.49% | 56 |
|
|
2021
Q2 | $16.7M | Buy |
389,463
+150,714
| +63% | +$6.34M | 0.98% | 13 |
|
|
2021
Q1 | $9.23M | Buy |
238,749
+2,915
| +1% | +$110K | 0.52% | 47 |
|
|
2020
Q4 | $8.48M | Buy |
+235,834
| New | +$8.5M | 0.43% | 79 |
|
|
2020
Q3 | – | Sell |
-752,567
| Closed | -$26.4M | – | 291 |
|
|
2020
Q2 | $26.4M | Buy |
752,567
+170,091
| +29% | +$6.13M | 1.39% | 13 |
|
|
2020
Q1 | $19M | Sell |
582,476
-82,362
| -12% | -$3.22M | 1.76% | 8 |
|
|
2019
Q4 | $30.1M | Buy |
664,838
+283,702
| +74% | +$11.9M | 1.56% | 7 |
|
|
2019
Q3 | $15.5M | Buy |
381,136
+107,202
| +39% | +$4.54M | 1.48% | 11 |
|
|
2019
Q2 | $11.8M | Buy |
273,934
+40,415
| +17% | +$1.55M | 1.33% | 19 |
|
|
2019
Q1 | $8.96M | Buy |
+233,519
| New | +$8.92M | 1.31% | 18 |
|
|
2018
Q2 | – | Sell |
-18,898
| Closed | -$516K | – | 261 |
|
|
2018
Q1 | $516K | Buy |
18,898
+7,417
| +65% | +$202K | 0.1% | 181 |
|
|
2017
Q4 | $285K | Buy |
+11,481
| New | +$317K | 0.34% | 68 |
|
|
2017
Q3 | – | Sell |
-47,756
| Closed | -$1.32M | – | 120 |
|
|
2017
Q2 | $1.32M | Buy |
+47,756
| New | +$1.27M | 0.5% | 45 |
|
|
2017
Q1 | – | Sell |
-24,686
| Closed | -$534K | – | 139 |
|
|
2016
Q4 | $534K | Sell |
24,686
-27,146
| -52% | -$592K | 1.11% | 29 |
|
|
2016
Q3 | $1.23M | Buy |
+51,832
| New | +$1.24M | 0.68% | 38 |
|
Other funds holding BSX
Edgestream Partners's BSX Position: Q2 2026 in Review
Edgestream Partners increased its Boston Scientific (BSX) stake by 77% in Q2 2026, buying an estimated $3.59M and bringing the position to 151,779 shares worth $6.48M. The position accounts for 0.19% of the portfolio, ranked #169.
Edgestream Partners first reported a position in BSX in Q3 2016 and has held it in 27 quarters since. The position peaked at $30.1M in Q4 2019. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Edgestream Partners held 151,779 shares of Boston Scientific worth $6.48M as of Q2 2026.
- Edgestream Partners bought 66,027 Boston Scientific shares in Q2 2026, an estimated $3.59M.
- Boston Scientific made up 0.19% of Edgestream Partners's portfolio in Q2 2026, its #169 holding.
- Edgestream Partners first reported a position in Boston Scientific in Q3 2016 and has held it in 27 quarters since.
- Edgestream Partners's Boston Scientific position peaked at $30.1M in Q4 2019.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Edgestream Partners's 13F filing for Q2 2026, filed 11 Aug 2026.